{"id":289573,"date":"2024-04-05T19:04:54","date_gmt":"2024-04-05T13:34:54","guid":{"rendered":"https:\/\/forumias.com\/blog\/?p=289573"},"modified":"2024-04-05T19:04:54","modified_gmt":"2024-04-05T13:34:54","slug":"nexcar19-indias-first-indigenous-car-t-cell-therapy","status":"publish","type":"post","link":"https:\/\/forumias.com\/blog\/nexcar19-indias-first-indigenous-car-t-cell-therapy\/","title":{"rendered":"NexCAR19: India’s first indigenous CAR T-cell therapy"},"content":{"rendered":"

Source<\/strong>– This post on NexCAR19: India’s first indigenous CAR T-cell therapy<\/strong> is based on the article “President of India Launches India\u2019s First Home-Grown Gene Therapy for Cancer<\/strong><\/a>” published in “PIB<\/strong>” on 4th April 2024.<\/p>\n

Why in the News?<\/h2>\n

The President of India recently launched India\u2019s first indigenous anti-cancer CAR-T cell therapy, NexCAR19, at IIT Bombay.<\/p>\n

What is NexCAR19?<\/h2>\n
\"NexCAR19\"
Source- Indian Express<\/strong><\/figcaption><\/figure>\n\n\n\n\n\n\n\n\n\n\n
Aspect<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n
About<\/strong><\/td>\nIt is India\u2019s first indigenously-developed CAR-T cell therapy.<\/a><\/td>\n<\/tr>\n
Developed by<\/strong><\/td>\nIIT Bombay<\/span>, Tata Memorial Centre<\/span> and ImmunoACT<\/span><\/td>\n<\/tr>\n
Purpose<\/strong><\/td>\nDesigned to target cancer cells carrying the CD19 protein.<\/span><\/td>\n<\/tr>\n
Recommended for<\/strong><\/td>\nPeople with B-cell lymphomas<\/span> who didn\u2019t respond to standard treatments like chemotherapy, leading to relapse or recurrence of the cancer.<\/td>\n<\/tr>\n
Treatment Process<\/strong><\/td>\n1.<\/strong> Patient donates blood at a transfusion centre. The blood goes to the lab, where the T-cells are genetically modified.
\n2.<\/strong> In a week to 10 days, these cells return to the clinic for patient reinfusion.<\/td>\n<\/tr>\n
Recovery<\/strong><\/td>\n1.<\/strong> Recovery typically occurs within two weeks<\/span> after one cycle of the treatment.
\n2.<\/strong> In the study conducted, approximately 70% of patients respond to the treatment, with variations between leukemia and lymphoma cases. About 50% of these responsive patients achieve a complete response.<\/td>\n<\/tr>\n
Significance<\/strong><\/td>\nIndia is one of the first developing countries to have its indigenous CAR-T and gene therapy platform.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

What is ImmunoAct?<\/h2>\n

1. About<\/strong>– Founded in 2018 as a spin-off from IIT-Bombay, ImmunoACT leads the way in pioneering India’s development of its first indigenous Cell & Gene Therapy.<\/p>\n

2. Mission<\/strong>– To ensure affordable access to innovative autologous CAR-T cell therapies.<\/p>\n

UPSC Syllabus- Science & Technology<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Source– This post on NexCAR19: India’s first indigenous CAR T-cell therapy is based on the article “President of India Launches India\u2019s First Home-Grown Gene Therapy for Cancer” published in “PIB” on 4th April 2024. Why in the News? The President of India recently launched India\u2019s first indigenous anti-cancer CAR-T cell therapy, NexCAR19, at IIT Bombay.… Continue reading NexCAR19: India’s first indigenous CAR T-cell therapy<\/span><\/a><\/p>\n","protected":false},"author":10367,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":""},"categories":[1566,1738],"tags":[11872,3590],"class_list":["post-289573","post","type-post","status-publish","format-standard","hentry","category-daily-factly-articles","category-science-and-technology-daily-factly-articles","tag-9pm-daily-factly","tag-pib","entry"],"jetpack_featured_media_url":"","views":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/289573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/users\/10367"}],"replies":[{"embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/comments?post=289573"}],"version-history":[{"count":0,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/posts\/289573\/revisions"}],"wp:attachment":[{"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/media?parent=289573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/categories?post=289573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/forumias.com\/blog\/wp-json\/wp\/v2\/tags?post=289573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}